Related Experiment Video
Updated: Apr 5, 2026

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
Published on: October 31, 2025
Low phosphatemia in extremely low birth weight neonates: A risk factor for hyperglycemia?
Lélia Dreyfus1, Céline Julie Fischer Fumeaux2, Laurent Remontet3
1Hospices Civils de Lyon, Service de Réanimation Néonatale et Néonatologie, Hôpital Femme Mère Enfant, Bron, France.
Insights
Low phosphate levels in extremely low birth weight (ELBW) neonates are linked to a higher risk of hyperglycemia. This finding suggests that managing phosphate may help prevent glucose intolerance in these vulnerable infants.
Area of Science:
- Neonatal Medicine
- Pediatric Endocrinology
- Metabolic Disorders
Background:
- Hyperglycemia affects over half of extremely low birth weight (ELBW) neonates, increasing morbidity and mortality.
- Hypophosphatemia is a common metabolic issue in ELBW infants.
- Existing research suggests a link between hypophosphatemia and glucose intolerance.
Purpose of the Study:
- To investigate the association between low phosphate levels (hypophosphatemia) and hyperglycemia in ELBW neonates.
- To determine if phosphatemia is a predictor of hyperglycemia in this population.
Main Methods:
- An observational study of 148 ELBW infants admitted to a tertiary neonatal care center.
- Routine measurement of phosphatemia and glycemia during parenteral nutrition.
- Statistical analysis using a joint model to assess the relationship between phosphate and hyperglycemia.
Main Results:
- 57% of ELBW infants in the study experienced hyperglycemia.
- A decrease in phosphate levels was significantly associated with an increased hazard of hyperglycemia.
- Each 0.41 mmol/L decrease in phosphate level multiplied the hazard of hyperglycemia by 3 (at the same time) and by 3.85 (the day before).
Conclusions:
- This study provides the first evidence suggesting a link between hypophosphatemia and hyperglycemia in ELBW neonates.
- Further research is needed to confirm if phosphate level management can prevent hyperglycemia in ELBW infants.
Background & Aims:
Hyperglycemia occurs in more than half of the extremely low birth weight (ELBW) neonates during the first weeks of life, and is correlated with an increased risk of morbi-mortality. Hypophosphatemia is another frequent metabolic disorder in this population. Data from animal, adult studies and clinical observation suggest that hypophosphatemia could induce glucose intolerance. Our aim was to determine whether a low phosphatemia is associated with hyperglycemia in ELBW neonates.
Methods:
This observational study included ELBW infants admitted in a tertiary neonatal care center (2010-2011). According to the center's policy, they received parenteral nutrition from birth and human milk from day 1. Phosphatemia and glycemia were measured routinely during parenteral nutrition. Hyperglycemia was defined by two consecutives values >8.3 mmol/L (150 mg/dL). Statistical analysis used a joint model combining a mixed-effects and a survival submodels to measure the association between phosphate and hyperglycemia.
Results:
The study included 148 patients. Mean gestational (Standard Deviation) age was 27.3 (1.6) weeks; mean birth weight was 803 (124) grams; 57% presented hyperglycemia. The multivariate joint model showed that the hazard of hyperglycemia at a given time was multiplied by 3 for each 0.41 mmol/L decrease of phosphate level at this time (p = 0.002) and by 3.85 for the same decreased of phosphate the day before (p = 0.0015).
Conclusion:
To our knowledge, this is the first study suggesting that low phosphatemia can be associated with hyperglycemia in ELBW neonates. Further studies will have to demonstrate whether better control of phosphatemia could help in preventing hyperglycemia.
Related Concept Videos
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Hypoglycemia and Glucagon
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Inborn Errors of Metabolism

